Ketorolac Tromethamine is the chemical name of the active ingredient used in Toradol and other ketorolac‑based formulations. It belongs to the NSAID class and is designed for short‑term management of acute moderate to severe pain, particularly in postoperative, trauma, and emergency settings. As a high‑potency non‑opioid analgesic, it provides rapid relief but is limited in duration due to gastrointestinal and renal safety considerations.
Ketorolac Tromethamine is available in several forms, including injection, oral tablets, nasal spray, and ophthalmic solutions. Each form delivers the same active molecule but differs in onset, absorption, and clinical use. This page provides a scientific overview of the molecule, its pharmacology, and its therapeutic role. For broader context, visit the Ketorolac overview page, and for injectable details see Toradol injection.
Ketorolac Tromethamine is the tromethamine salt form of ketorolac, a potent non‑steroidal analgesic molecule. The chemical structure includes a pyrrolizine carboxylic acid core, which contributes to its strong COX‑inhibiting activity. The tromethamine component is not pharmacologically active; it is added to improve solubility, stability, and suitability for injectable and oral formulations. Ketorolac base is poorly soluble in water, while the tromethamine salt dissolves efficiently, enabling rapid systemic absorption. This salt form is used across all major ketorolac products, including injections, tablets, nasal spray, and ophthalmic solutions.
Ketorolac Tromethamine belongs to the NSAID class and is categorized as a high‑potency non‑opioid analgesic. Unlike traditional NSAIDs used primarily for inflammation, ketorolac is optimized for short‑term management of acute moderate to severe pain. Its strong prostaglandin‑blocking activity produces analgesia comparable to weaker opioids but without opioid‑related effects. The molecule’s potency and COX‑1/COX‑2 inhibition profile explain both its effectiveness and its strict duration limits. The tromethamine salt does not alter pharmacodynamics but ensures consistent delivery across different dosage forms.
Ketorolac Tromethamine works by inhibiting cyclooxygenase enzymes COX‑1 and COX‑2, which reduces the synthesis of prostaglandins — key mediators of pain and inflammation. This strong suppression of prostaglandin pathways produces rapid and pronounced analgesia, making ketorolac significantly more potent than common NSAIDs such as ibuprofen or naproxen.
The analgesic effect is primarily peripheral, not central, which distinguishes ketorolac from opioids. It does not act on opioid receptors and does not produce opioid‑related effects such as sedation or respiratory depression. Instead, its potency comes from high‑affinity COX inhibition, which reduces pain signaling at the tissue level.
Because prostaglandins also protect the gastrointestinal lining and support renal blood flow, strong inhibition increases the risk of GI irritation and kidney stress. This is why ketorolac is used only short‑term. More details on timing characteristics are available on the Toradol onset & duration page.
Ketorolac Tromethamine is available in multiple pharmaceutical forms, each designed for rapid short‑term analgesia. Injectable formulations include 20 mg, 30 mg, and 60 mg strengths, with 30 mg being the most commonly used in clinical settings. More details are available on the Ketorolac 30 mg injection and Ketorolac 60 mg injection pages.
Oral tablets contain 10 mg of Ketorolac Tromethamine and are typically used as continuation therapy after injections. They provide moderate onset and are not intended for immediate stabilization. More information is available on the Ketorolac 10 mg page.
Nasal ketorolac offers fast absorption without injections and is used in outpatient scenarios where rapid non‑invasive relief is preferred. Additional details can be found on the Toradol nasal spray page.
Ophthalmic ketorolac (Acular) is formulated for local use in the eye to manage postoperative ocular pain and inflammation. It delivers the same active molecule but with minimal systemic exposure.
Although all forms contain Ketorolac Tromethamine, they differ in onset, absorption rate, and clinical application. Injections provide the fastest effect, tablets extend analgesia briefly, nasal spray offers rapid outpatient relief, and ophthalmic drops target localized ocular pain.
Ketorolac Tromethamine is used for short‑term management of acute moderate to severe pain. It is commonly administered after surgery to provide rapid postoperative analgesia during the early recovery phase. Its fast onset makes it suitable for stabilizing pain immediately after anesthesia.
Trauma‑related pain is another major indication. Musculoskeletal injuries, sprains, contusions, and acute flare‑ups often require strong non‑opioid analgesia. More details are available on the Toradol for pain page.
In some clinical settings, Ketorolac Tromethamine may be used for acute migraine episodes. It is not a preventive therapy but may help reduce pain intensity during an acute attack. Additional information is available on the Toradol for migraine page.
Ophthalmic ketorolac (Acular) is used for postoperative ocular pain and inflammation, providing localized relief with minimal systemic exposure.
The onset of Ketorolac Tromethamine varies by form. Injections provide the fastest effect, with rapid systemic absorption. Nasal ketorolac also offers fast onset, though slightly slower than IV administration. Oral tablets have a moderate onset and are typically used as continuation therapy rather than for immediate stabilization.
Duration is moderate across all forms. It is long enough to manage acute pain episodes but not long enough to support chronic therapy. This moderate duration aligns with ketorolac’s safety profile, which emphasizes limiting exposure to reduce gastrointestinal and renal risks.
Because of its onset and duration characteristics, Ketorolac Tromethamine is used only short‑term. More details on duration limits are available on the Toradol short-term use page.
Ketorolac Tromethamine is the chemical name of the active ingredient, while Toradol is the brand name under which ketorolac products are marketed. Both refer to the same molecule and provide identical analgesic effects. The difference lies in naming, not in pharmacology or clinical performance.
Toradol products contain Ketorolac Tromethamine in various forms, including injections, tablets, nasal spray, and ophthalmic solutions. The brand name is used for commercial identification, while the chemical name is used in scientific and regulatory contexts.
Ketorolac Tromethamine differs from common NSAIDs such as ibuprofen, naproxen, and diclofenac in both potency and duration limitations. While ibuprofen and naproxen are used for mild to moderate pain and can be taken for longer periods, ketorolac is significantly stronger and therefore restricted to short‑term use only.
Naproxen provides longer-lasting anti-inflammatory effects but has a slower onset than ketorolac. Diclofenac is stronger than ibuprofen but still generally less potent than ketorolac. Ketorolac’s high potency makes it effective for acute high‑intensity pain but also increases the risk of gastrointestinal and renal complications when used repeatedly.
More comparative details are available on the Toradol vs Ibuprofen and Toradol vs Naproxen pages.
Ketorolac Tromethamine shares the typical NSAID side‑effect profile but with higher intensity due to its strong COX‑1/COX‑2 inhibition. Common side effects include nausea, stomach discomfort, dizziness, headache, and fluid retention. These effects are generally mild but occur more frequently than with standard NSAIDs because ketorolac produces a more pronounced prostaglandin‑blocking effect.
Serious risks include gastrointestinal irritation, ulcers, bleeding, and renal stress. These risks increase with repeated dosing or prolonged use, which is why ketorolac is strictly limited to short‑term therapy. The strong inhibition of protective prostaglandins makes the GI tract and kidneys more vulnerable, especially in sensitive individuals.
Injectable forms may cause local reactions such as soreness, swelling, or discomfort at the injection site. IV administration may cause brief irritation at the venous access point. These effects are typically mild and short‑lived.
Oral tablets may cause more noticeable gastrointestinal effects because they pass through the digestive tract. Although systemic risks remain the same across all forms, oral ketorolac may produce more stomach‑related discomfort compared with injections or nasal spray.
Ketorolac Tromethamine is contraindicated in individuals with active gastrointestinal ulcers, recent GI bleeding, or a history of perforation. Because ketorolac strongly suppresses prostaglandins, it can worsen these conditions. It is also avoided in patients with severe kidney impairment due to the risk of reduced renal blood flow.
Age‑related considerations apply, as older adults may be more susceptible to gastrointestinal and renal side effects. Ketorolac is intended strictly for short‑term use, and even brief therapy is performed with caution in sensitive populations.
Combining ketorolac with other NSAIDs is generally avoided because it increases the risk of gastrointestinal irritation, kidney stress, and bleeding. Caution is also required in individuals with bleeding disorders, dehydration, cardiovascular risk factors, or conditions that may worsen with prostaglandin inhibition.
| Form | Dosage | Route | Onset | Duration |
|---|---|---|---|---|
| Injection | 20/30/60 mg | IM/IV | Fast | Moderate |
| Tablets | 10 mg | Oral | Moderate | Moderate |
| Nasal | — | Nasal | Fast | Moderate |
| Acular | 0.5% | Ophthalmic | Fast | Short |
All forms contain the same active molecule but differ in onset, absorption, and clinical application. Injections provide the fastest systemic effect, tablets extend analgesia briefly, nasal spray offers rapid non‑invasive relief, and ophthalmic drops target local ocular pain with minimal systemic exposure.
| Medication | Strength | Speed | Risks | Used For |
|---|---|---|---|---|
| Ketorolac | High | Fast | Moderate / High | Acute pain |
| Ibuprofen | Moderate | Moderate | Low | Mild / Moderate pain |
| Naproxen | Moderate | Slow | Moderate | Inflammation |
Ketorolac is significantly stronger than common NSAIDs, which explains its use in acute high‑intensity pain. However, this potency also increases systemic risks, limiting its duration of use. Ibuprofen and naproxen are safer for long‑term therapy, while ketorolac is reserved for short‑term scenarios requiring rapid, strong analgesia.
| Form | Onset | Duration |
|---|---|---|
| Injection | Fast | Moderate |
| Oral | Moderate | Moderate |
| Nasal | Fast | Moderate |
Although onset varies by route, duration remains moderate across all forms due to ketorolac’s consistent pharmacokinetic profile. This balance of fast onset and moderate duration supports its role as a short‑term analgesic rather than a chronic therapy option.
| Parameter | Ketorolac Base | Ketorolac Tromethamine |
|---|---|---|
| Solubility | Low | High |
| Bioavailability | Lower | Higher |
| Use | Limited | Clinical |
Ketorolac base is poorly soluble and not suitable for most pharmaceutical formulations. Ketorolac Tromethamine, the tromethamine salt, offers superior solubility and bioavailability, making it the standard clinical form used in injections, tablets, nasal spray, and ophthalmic solutions.